IL17A and psoriasis: Current treatment strategies in modern medicine emphasize etiological treatment to alleviate SDs and psoriasis, such as benzodiazepines for sleep and biologics targeting IL-17, IL23, or TNF-α that inhibit IL-23/Th17 pro-inflammatory signaling axis and improve antioxidant capability to suppress chronic inflammation and halt the progression of psoriasis (Mihu et al., 2021; Blagov et al., 2023).